Chronic Pain, that persists beyond the usual recovery period or occurs along with a chronic health condition, such as arthritis. The rising prevalence of chronic pain drives market growth by ...

After a nearly $300 million IPO little more than a year ago, a young Peninsula biotech company will discontinue what had been ...

The MM120 ODT Phase 3 clinical development program also includes the Voyage study for GAD and the Emerge study for major depressive disorder (MDD). The U.S. Food and Drug Administration has granted ...

HB-500 is a next-generation therapeutic vaccine being developed in collaboration with Gilead Sciences, Inc. (Gilead) as a potential component of a curative regimen for human immunodeficiency virus (HI ...

The COVID-19 pandemic forced investigators conducting clinical trials to use decentralized elements, such as telehealth, to ...

SAN CARLOS, Calif. - CARGO Therapeutics , Inc. (NASDAQ:CRGX), a clinical-stage biotech company currently valued at $628 ...

Inc. stock despite strong Phase 2b data. Click for my updated look at MNMD stock and its market opportunities.

The interim leader of the National Institutes of Health gave some clarification tied to Trump administrations restrictions on ...

Budget 2025 hopes to extend financial incentives to clinical research industry for developing cutting-edge therapies in India ...

A new study shows that oral fecal microbiota transplantation (FMT) is a feasible and safe addition to preventing graft-versus-host disease in patients undergoing stem cell transplantation for blood ...

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and ...